One More IVD Enterprise Sprinted for STAR Market

On Sep. 25th, Upper Biotech applied for IPO was accepted by Shanghai Stock Exchange. At present, it has 7 listed enterprise on STAR Market, 2 registered upcoming companies and 5 waitings. At this time, Upper tried to raise ￥262.53 million updating intellectual POCT project for construction of manufacturing base and R&D center which will improve the capability of research and productivity. The listing standards that Upper chose is the anticipated marketing value by no less than one billion RMB with no less than 50 million RMB net margin in recent 2 years, or to choose the anticipated marketing value by no less than one billion RMB with no less than 100 million RMB net margin in a year.

Established in 1994, Upper Biotech is a growing in vitro diagnostic manufacturer specialized in POCT (point of care testing) area. Its expertise covers the entire value chain, starting from R&D to the manufacturing of reagent kits, the design & production of IVD diagnostic devices, distribution and sales. Upper Biotech is located in Shanghai Hi-Tech Medical Device Park, China. The company took the advantages of detection of inflammation and infection based on the understanding of POCT & clinical application to establish a core platform with the method of latex lmmunoturbidimetry, fluorescence immunoassay and GICA integrated the technologies of automatics, whole-blood sample test and big data acquisition to satisfying the demands from medical institutes.

With 66 patients and 41 items of medical device registration certificate approved by NMPA, the company sustains on clinical R&D based on proprietary intellectual property rights which has been widely applied to inflammatory Infectious detection, contagion detection, cardio-cerebrovascular detection, glycometablism detection, nephropathy detection, etc. Upper won a certain competitive position and reputation on POCT segment.

Upper released 2 professional monographs of iPOCT and Intellectual Poct, pushed the national standardization of GB/T29790-2013, established variety of proprietary intellectual property rights on digital bioinformatics technology, automatic loading technology,  time-resolved fluorometry (TRF), ionic-homogeneous calibration and so on, and developed SAA reagent for bacteria and virus identification. Moreover, the company created an automatic intellectual diagnostic platform and data center with wisdom diagnosis and healthy pattern bringing precision advantages to children` s disease.